ICN GALENIKA SHARE OWNERSHIP
Around 4,000 of the 5,300 workers employed by ICN Galenika of Belgrade, capital of the former Yugoslavia, now own shares in SPI Pharmaceuticals, which is the majority shareholder in ICN Galenika, according to reports from the Tanjug news agency. SPI Pharmaceuticals is a subsidiary of ICN Pharmaceuticals of the USA, which is owned by Milan Panic, Prime Minister of Yugoslavia.
Meantime, Galenika, which is also a shareholder in ICN Galenika, has taken control of the Glina baby food company in the self-proclaimed Serbian Republic of Krajina, which is inside the Republic of Croatia, says the Tanjug agency.
Galenika will be able to sell dehydrated baby food, vegetable soups and vitamin-enriched food products from Glina's production program. Glina exported baby food worth around $11.5 million in 1991.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze